Upload
pallav-singh
View
221
Download
0
Embed Size (px)
Citation preview
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
1/77
A
PROJECT REPORT
ON
A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2
PROTEIN IN H1N1
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
2/77
CONTENTS
Abstract
Introduction
I. Proteins
II. Drug Designing
III. Active Site in Drug Designing
Review OF
Methodology
Result and dissuasion
Results
Conclusion
References
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
3/77
Today Information Technology is highly involved in all Biotechnology and
Pharmacology research and development sectors to understand biological
data, their properties, functions and individual role in the metabolites of a
living organism.
Computer Aided Drug Designing (CADD) is also an involvement of
information technology in pharmacology studies. This technology makes
easy to understand biomolecules and biochemical reactions. This method is
based on receptor and inhibitors interaction theory, in technical term it is
called Docking.
Virtual screening uses computer-based methods to discover new ligands on
the basis of biological structures. Large libraries are available, compounds
are docked into the structure of receptor targets by a docking computer
program.
Each compound is sampled in thousands to millions of possible
configurations and scored on the basis of its complementarity to the receptor.
Of the hundreds of thousands of molecules in the library, tens of top-scoring
predicted ligands (hits) are subsequently tested for activity in an
experimental assay.
This project aims to demonstrating Linux platform software based docking
dramatically into the process of discovery new drug that bind to biological
micro molecules with clear benefit for both the pharmaceutical industry and
whole social community .
Abstrac
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
4/77
Initially I have focused on the M2protein of H1N1 which is an matrix
protein, enables hydrogen ions to enter the viral particle (virion) from
the endosome, thus lowering pH of the inside of the virus, which
causes dissociation of the viral partical and work on computational
docking to study the model ligands amantadine and rimantadine, and
collected the library of 100 ligands; to inhibit the receptor M2protein,
in the computational methodology which is useful in Virtual Screening
for finding the minimum scored inhibitors from the ligands library.
However the results achieved demonstrate that high power computer
clustering software services technology (HPCCSN), networking technology
and Linux platform can be useful in applied drug design.
http://en.wikipedia.org/wiki/Virionhttp://en.wikipedia.org/wiki/Endosomehttp://en.wikipedia.org/wiki/Virionhttp://en.wikipedia.org/wiki/Endosome8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
5/77
Chapter-1
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
6/77
Computer aided drug design CADD):
Computer aided drug design may be defined as the use of computational
techniques to design new drugs or drug molecule /to discovery new drugs.
1. Computer-Aided Drug Design (CADD) is a specialized discipline that
uses computational methods to simulate drug-receptor interactions.
CADD methods are heavily dependent on bioinformatics tools,
applications and databases. As such, there is considerable overlap in
CADD research and bioinformatics.
2. http://www.b-eye-network.com/view/852
BENIFITES OF CADD:
CADD methods and bioinformatics tools offer significant benefits for drug
discovery programs which are as follow.
Cost saving
The tuff report suggests that the cost of drug discovery and development
has reached $800 million for each drug successfully brought to market.
Many biopharmaceutical companies now use computational methods and
bioinformatics tools to reduce this cost burden. Virtual screening, lead
optimization and predictions of bioavailability and bioactivity can help
guide experimental research. Only the most promising experimental lines
of inquiry can be followed and experimental dead-ends can be avoided
early based on the results of CADD simulations.
Time-to-Market :
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
7/77
The predictive power of CADD can help drug research programs choose
only the most promising drug candidates. By focusing drug research on
specific lead candidates and avoiding potential dead-end compounds,
biopharmaceutical companies can get drugs to market more quickly.
Insight :
One of the non-quantifiable benefits of CADD and the use of
bioinformatics tools is the deep insight that researchers acquire about
drug-receptor interactions. Molecular models of drug compounds can
reveal intricate, atomic scale binding properties that are difficult toenvision in any other way. When we show researchers new molecular
models of their putative drug compounds, their protein targets and how
the two bind together, they often come up with new ideas on how to
modify the drug compounds for improved fit. This is an intangible benefit
that can help design research programs. .
RECEPETOR
such binding occurs, the receptor goes into a conformational change which
ordinarily initiates a cellular response. However, some ligands merely block
receptors without inducing any response (e.g. antagonists). Ligand-induced
activity of the ligands changes in receptors result in physiological changes
which constitute the biological. In biochemistry, a receptor is a protein
molecule, embedded in either the plasma membrane orcytoplasm of a cell,to which a mobile signaling (or "signal") molecule may attach. A molecule
which binds to a receptor is called a "ligand," and may be a peptide (such as
a neurotransmitter), a hormone, a pharmaceutical drug, or a toxin, and when
http://en.wikipedia.org/wiki/Biochemistryhttp://en.wikipedia.org/wiki/Proteinhttp://en.wikipedia.org/wiki/Plasma_membranehttp://en.wikipedia.org/wiki/Cytoplasmhttp://en.wikipedia.org/wiki/Ligand_(biochemistry)http://en.wikipedia.org/wiki/Neurotransmitterhttp://en.wikipedia.org/wiki/Hormonehttp://en.wikipedia.org/wiki/Biochemistryhttp://en.wikipedia.org/wiki/Proteinhttp://en.wikipedia.org/wiki/Plasma_membranehttp://en.wikipedia.org/wiki/Cytoplasmhttp://en.wikipedia.org/wiki/Ligand_(biochemistry)http://en.wikipedia.org/wiki/Neurotransmitterhttp://en.wikipedia.org/wiki/Hormone8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
8/77
http://en.wikipedia.org/wiki/Receptor_(biochemistry)
http://upload.wikimedia.org/wikipedia/commons/0/07/Transmembrane_
receptor.png
DRUG:
Drugs are chemical subestances thet specifically interact with specific
biological recepeter and increase or decrease its activity.
A drug, broadly speaking, is any substance that, when absorbed into the
body of a living organism, alters normal bodily function.
Pharmacology,defines a drug as "a chemical substance used in the
treatment, cure, prevention, or diagnosis of disease or used to otherwise
enhance physical or mental well-being.
Drugs are usually distinguished from endogenous biochemicals by being
introduced from outside the organism. For example, insulin is a hormone
that is synthesized in the body; it is called a hormone when it is synthesized
http://en.wikipedia.org/wiki/Pharmacologyhttp://en.wikipedia.org/wiki/Chemicalhttp://en.wikipedia.org/wiki/Endogenoushttp://en.wikipedia.org/wiki/Insulinhttp://en.wikipedia.org/wiki/Pharmacologyhttp://en.wikipedia.org/wiki/Chemicalhttp://en.wikipedia.org/wiki/Endogenoushttp://en.wikipedia.org/wiki/Insulin8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
9/77
by the pancreas inside the body, but if it is introduced into the body from
outside, it is called a drug.
http://en.wikipedia.org/wiki/Drug
http://www.scleroderma.org/images/med
icalimages/research_advances/Figure-3_Receptor-Ligand.jpg
Virtual Screening:
Virtual screening (VS) is a computational technique used in drug discovery
research. It involves the rapid in silico assessment of large libraries of
chemical structures in order to identify those structures most likely to bind to
a drug target, typically aproteinreceptororenzyme.
Virtual screening has become an integral part of the drug discovery process.
Related to the more general and long pursued concept of database searching,
the term "virtual screening" is relatively new. Walters, et al. define virtual
screening as "automatically evaluating very large libraries of compounds"
using computer programs.[
http://en.wikipedia.org/wiki/Drug_discoveryhttp://en.wikipedia.org/wiki/In_silicohttp://en.wikipedia.org/wiki/Proteinhttp://en.wikipedia.org/wiki/Receptor_(biochemistry)http://en.wikipedia.org/wiki/Enzymehttp://en.wikipedia.org/wiki/Virtual_screening#cite_note-Walters_1998-2%23cite_note-Walters_1998-2http://en.wikipedia.org/wiki/Drug_discoveryhttp://en.wikipedia.org/wiki/In_silicohttp://en.wikipedia.org/wiki/Proteinhttp://en.wikipedia.org/wiki/Receptor_(biochemistry)http://en.wikipedia.org/wiki/Enzymehttp://en.wikipedia.org/wiki/Virtual_screening#cite_note-Walters_1998-2%23cite_note-Walters_1998-28/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
10/77
The purpose of virtual screening to come up with hits of novel chemical
structure that bind to the macromolecular target of interest. Thus, success of
a virtual screen is defined in terms of finding interesting new scaffolds rather
than many hits. Interpretations of VS accuracy should therefore be
considered with caution. Low hit rates of interesting scaffolds are clearly
preferable over high hit rates of already known scaffolds.
Method :
There are two broad categories of screening techniques: ligand-based and
structure-based.
1. Ligand-based method
Given a set of structurally diverse ligands that binds to a receptor, a model of
the receptor can be built based on what binds to it. These are known as
pharmacophore models. A candidate ligand can then be compared to the
pharmacophore model to determine whether it is compatible with it and
therefore likely to bin
Another approach to ligand-based virtual screening is to use chemical
similarity analysis methods to scan a database of molecules against one
active ligand structure.
2. Structure-based
Structure-based virtual screening involves docking of candidate ligands into
a protein target followed by applying a scoring function to estimate the
likelihood that the ligand will bind to the protein with high affinity.
http://en.wikipedia.org/wiki/Virtual_screening#cite_note-Walters_1998-2%23cite_note-Walters_1998-2http://en.wikipedia.org/wiki/Virtual_screening#cite_note-Walters_1998-2%23cite_note-Walters_1998-2http://en.wikipedia.org/wiki/Virtual_screening#cite_note-Walters_1998-2%23cite_note-Walters_1998-2http://en.wikipedia.org/wiki/Virtual_screening#cite_note-Walters_1998-2%23cite_note-Walters_1998-2http://en.wikipedia.org/wiki/Virtual_screening#cite_note-Walters_1998-2%23cite_note-Walters_1998-2http://en.wikipedia.org/wiki/Virtual_screening#cite_note-Walters_1998-2%23cite_note-Walters_1998-2http://en.wikipedia.org/wiki/Virtual_screening#cite_note-Walters_1998-2%23cite_note-Walters_1998-2http://en.wikipedia.org/wiki/Virtual_screening#cite_note-Walters_1998-2%23cite_note-Walters_1998-2http://en.wikipedia.org/wiki/Virtual_screening#cite_note-Walters_1998-2%23cite_note-Walters_1998-2http://en.wikipedia.org/wiki/Virtual_screening#cite_note-Walters_1998-2%23cite_note-Walters_1998-2http://en.wikipedia.org/wiki/Virtual_screening#cite_note-Walters_1998-2%23cite_note-Walters_1998-2http://en.wikipedia.org/wiki/Virtual_screening#cite_note-Walters_1998-2%23cite_note-Walters_1998-2http://en.wikipedia.org/wiki/Pharmacophorehttp://en.wikipedia.org/wiki/Docking_(molecular)http://en.wikipedia.org/wiki/Scoring_functions_for_dockinghttp://en.wikipedia.org/wiki/Pharmacophorehttp://en.wikipedia.org/wiki/Docking_(molecular)http://en.wikipedia.org/wiki/Scoring_functions_for_docking8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
11/77
Ap plications:
Virtuale screening useful in folloing situations.
The number avilable compounds in a library greatly exceeds the
experimentally based "wet" screen capacity to evaluate these
compounds. Virtual screening can then be used to prioritize
compounds for screening thereby identifying a greater number of hits
than could be identified by screening a random subset of compounds
selected from the same library.
The number of compounds that could be synthesized using
combinatorial chemistry methods greatly exceeds the synthetic
capacity. Virtual screening can be used to screen a virtual library of
compounds that could be synthesized to identify those most likely to
bind. Then synthetic capacity can be focused on those compounds.
http://en.wikipedia.org/wiki/Virtual_screening
Chapter-2
H1N1:
http://en.wikipedia.org/wiki/Combinatorial_chemistryhttp://en.wikipedia.org/wiki/Combinatorial_chemistry8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
12/77
Influenza A(H1N1) virus is a subtype of influenzavirus A and the most
common cause of influenza (flu) in humans. Some strains of H1N1 are
endemic in humans and cause a small fraction of all influenza-like illness
and a large fraction of all seasonal influenza. H1N1 strains caused roughly
half of all human flu infections in 2006. Other strains of H1N1 are endemic
in pigs (swine influenza) and in birds (avian influenza).
In June 2009, WHO declared that flu due to a new strain of swine-origin
H1N1 was responsible for the 2009 flu pandemic. This strain is commonly
called "swine flu" by the public media.
http://en.wikipedia.org/wiki/Influenza_A_virus_subtype_H1N1
http://en.wikipedia.org/wiki/Influenzavirus_Ahttp://en.wikipedia.org/wiki/Influenzahttp://en.wikipedia.org/wiki/Human_influenzahttp://en.wikipedia.org/wiki/Influenza-like_illnesshttp://en.wikipedia.org/wiki/Seasonal_influenzahttp://en.wikipedia.org/wiki/Swine_influenzahttp://en.wikipedia.org/wiki/Swine_influenzahttp://en.wikipedia.org/wiki/Avian_influenzahttp://en.wikipedia.org/wiki/WHOhttp://en.wikipedia.org/wiki/2009_flu_pandemichttp://en.wikipedia.org/wiki/Influenza_A_virus_subtype_H1N1http://en.wikipedia.org/wiki/Influenzavirus_Ahttp://en.wikipedia.org/wiki/Influenzahttp://en.wikipedia.org/wiki/Human_influenzahttp://en.wikipedia.org/wiki/Influenza-like_illnesshttp://en.wikipedia.org/wiki/Seasonal_influenzahttp://en.wikipedia.org/wiki/Swine_influenzahttp://en.wikipedia.org/wiki/Swine_influenzahttp://en.wikipedia.org/wiki/Avian_influenzahttp://en.wikipedia.org/wiki/WHOhttp://en.wikipedia.org/wiki/2009_flu_pandemichttp://en.wikipedia.org/wiki/Influenza_A_virus_subtype_H1N18/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
13/77
Fig: This image showing structure of H1N1.
NOMENCULTURE :
Influenza A virus strains are categorized according to two proteins found on
the surface of the virus: hemagglutinin (H) and neuraminidase (N). All
influenza A viruses contain hemagglutinin and neuraminidase, but the
http://en.wikipedia.org/wiki/Influenza_A_virus_subtype_H1N1http://en.wikipedia.org/wiki/Influenza_A_virus_subtype_H1N1http://en.wikipedia.org/wiki/Influenza_A_virushttp://en.wikipedia.org/wiki/Hemagglutinin_(influenza)http://en.wikipedia.org/wiki/Viral_neuraminidasehttp://en.wikipedia.org/wiki/Influenza_A_virushttp://en.wikipedia.org/wiki/Hemagglutinin_(influenza)http://en.wikipedia.org/wiki/Viral_neuraminidase8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
14/77
structures of these proteins differ from strain to strain, due to rapid genetic
mutation in the viral genome.
Influenza A virus strains are assigned an H number and an N number based
on which forms of these two proteins the strain contains. There are 16 H and
9 N subtypes known in birds, but only H 1, 2 and 3, and N 1 and 2 are
commonly found in humans.
Classification
Of the three genera of influenza viruses that cause human flu, two also cause
influenza in pigs, with influenza A being common in pigs and influenza C
being rare. Influenza B has not been reported in pigs. Within influenza A
and influenza C, the strains found in pigs and humans are largely distinct,
although due to reassortment there have been transfers of genes among
strains crossing swine, avian, and human species boundaries.
Influenza C
Influenza C viruses infect both humans and pigs, but do not infect birds.
Transmission between pigs and humans have occurred in the past.For
example, influenza C caused small outbreaks of a mild form of influenza
amongst children in Japan and California. Due to its limited host range and
the lack of genetic diversity in influenza C, this form of influenza does not
cause pandemics in humans.
Influenza A
Swine influenza is known to be caused by influenza A subtypes H1N1,
H1N2, H3N1, H3N2, and H2N3. In pigs, three influenza A virus subtypes
http://en.wikipedia.org/wiki/Genetic_mutationhttp://en.wikipedia.org/wiki/Genetic_mutationhttp://en.wikipedia.org/wiki/Generahttp://en.wikipedia.org/wiki/Human_fluhttp://en.wikipedia.org/wiki/Influenzavirus_Ahttp://en.wikipedia.org/wiki/Influenzavirus_Chttp://en.wikipedia.org/wiki/Influenzavirus_Bhttp://en.wikipedia.org/wiki/Reassortmenthttp://en.wikipedia.org/wiki/H1N1http://en.wikipedia.org/wiki/H1N2http://en.wikipedia.org/wiki/H3N1http://en.wikipedia.org/wiki/H3N2http://en.wikipedia.org/wiki/H2N3http://en.wikipedia.org/wiki/Genetic_mutationhttp://en.wikipedia.org/wiki/Genetic_mutationhttp://en.wikipedia.org/wiki/Generahttp://en.wikipedia.org/wiki/Human_fluhttp://en.wikipedia.org/wiki/Influenzavirus_Ahttp://en.wikipedia.org/wiki/Influenzavirus_Chttp://en.wikipedia.org/wiki/Influenzavirus_Bhttp://en.wikipedia.org/wiki/Reassortmenthttp://en.wikipedia.org/wiki/H1N1http://en.wikipedia.org/wiki/H1N2http://en.wikipedia.org/wiki/H3N1http://en.wikipedia.org/wiki/H3N2http://en.wikipedia.org/wiki/H2N38/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
15/77
(H1N1, H3N2, and H1N2) are the most common strains worldwide. In the
United States, the H1N1 subtype was exclusively prevalent among swine
populations before 1998; however, since late August 1998, H3N2 subtypes
have been isolated from pigs. As of 2004, H3N2 virus isolates in US swine
and turkey stocks were triple reassortants, containing genes from human
(HA, NA, and PB1), swine (NS, NP, and M), and avian (PB2 and PA)
lineages.
http://en.wikipedia.org/wiki/Influenza_A_virus_subtype_H1N1
(H1N1) pandemic :
In the 2009 flu pandemic, the virus isolated from patients in the United
States was found to be made up of genetic elements from four different flu
viruses North American Mexican influenza, North American avian
influenza, human influenza, and swine influenza virus typically found in
Asia and Europe "an unusually mongrelised mix of genetic sequences.
This new strain appears to be a result of reassortment ofhuman influenzaand swine influenza viruses, in all four different strains of subtype H1N1.
Preliminary genetic characterization found that the hemagglutinin (HA) gene
was similar to that of swine flu viruses present in U.S. pigs since 1999, but
the neuraminidase (NA) and matrix protein (M) genes resembled versions
present in European swine flu isolates. The six genes from American swine
flu are themselves mixtures of swine flu, bird flu, and human flu viruses.
While viruses with this genetic makeup had not previously been found to be
circulating in humans or pigs, there is no formal national surveillance system
to determine what viruses are circulating in pigs in the U.S. On June 11,
http://en.wikipedia.org/wiki/United_Stateshttp://en.wikipedia.org/wiki/Reassortmenthttp://en.wikipedia.org/wiki/Human_fluhttp://en.wikipedia.org/wiki/Avian_influenzahttp://en.wikipedia.org/wiki/2009_flu_pandemichttp://en.wikipedia.org/wiki/2009_flu_pandemic_virushttp://en.wikipedia.org/wiki/Mongrelizationhttp://en.wikipedia.org/wiki/Reassortmenthttp://en.wikipedia.org/wiki/Human_influenzahttp://en.wikipedia.org/wiki/Swine_influenzahttp://en.wikipedia.org/wiki/Hemagglutinin_(influenza)http://en.wikipedia.org/wiki/Neuraminidasehttp://en.wikipedia.org/wiki/Matrix_proteinhttp://en.wikipedia.org/wiki/United_Stateshttp://en.wikipedia.org/wiki/Reassortmenthttp://en.wikipedia.org/wiki/Human_fluhttp://en.wikipedia.org/wiki/Avian_influenzahttp://en.wikipedia.org/wiki/2009_flu_pandemichttp://en.wikipedia.org/wiki/2009_flu_pandemic_virushttp://en.wikipedia.org/wiki/Mongrelizationhttp://en.wikipedia.org/wiki/Reassortmenthttp://en.wikipedia.org/wiki/Human_influenzahttp://en.wikipedia.org/wiki/Swine_influenzahttp://en.wikipedia.org/wiki/Hemagglutinin_(influenza)http://en.wikipedia.org/wiki/Neuraminidasehttp://en.wikipedia.org/wiki/Matrix_protein8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
16/77
2009, the WHO declared an H1N1 pandemic, moving the alert level to phase
6, marking the first global pandemic since the 1968 Hong Kong flu.
http://upload.wikimedia.org/wikipedia/commons/d/d0/AntigenicShift_H
iRes.png
How H1N1 causes flu(Mechanism of pathogenesis):
http://en.wikipedia.org/wiki/Hong_Kong_fluhttp://en.wikipedia.org/wiki/Hong_Kong_flu8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
17/77
Flu is caused by a virus called Influenza virus and mainly affects the
respiratory tract.
Mode of transmission - Droplet borne, or air borne i.e., when a person
sneezes or coughs, large number of infectious droplets gets dispersed in air
and when these are inhaled they infect others. Hence it spreads very fast
from person to person and has a potential to cause pandemic
Mechanism or Pathogenesis - the virus has 2 important antigens
1)Neuraminidase(N)
2)Hemaglutinin(H)
Depending on these only H1N1 is classified.. It has the tendency to change
its serotype, like previously it was caused by H5N1 so on.
When person inhales a virus partical, it gets to the respiratory epithelial cells
with the help of hem agglutinin and enters the cells with the help of
neuraminidase. It replicates inside the cells and spreads the neighbouring
cells. Remember it does not enter blood usually its infection is only confine
to respiratory epithelium.
The epithelium gets damaged, which invites secondary bacterial infections.
The person suffers from a bacterial pneumonia. Person dies of secondary
bacterial infection. Not because of flu as such. Many a times or most of the
times the flu is just confined to respiratory system without any secondary
infection and hence most of the people just suffer from a just a short duration
of cold or cough. But they transmit the infection.
Once infected, the person starts infecting others with the release of the
infectious particles into the air.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
18/77
http://in.answers.yahoo.com/question/index?
qid=20090625044628AAa7nDu
M2 protein:
Introduction
The M2 protein is aproton-selective ion channelprotein, integral in the viral
envelope of the influenza A virus. The channel itself is a homotetramer
(consists of four identical M2 units), where the units are helices stabilized by
two disulfide bonds. It is activated by lowpH.
Structure
Fig: M2 Protein of H1N1
The M2 protein unit consists of threeprotein domains: the 24 amino acids on
theN-terminal end, exposed to the outside environment, the 19 hydrophobic
amino acids on the transmembrane region, and the 54 amino acids on the C-
terminal end, oriented towards the inside of the viral particle. Two different
high-resolution structures of truncated forms of M2 have been reported: the
structure of a mutated form of the M2 transmembrane region by itself , as
well as a longer version of the protein containing only naturally-occurring
sequence in the transmembrane region. The two structures also suggest
different binding sites for the adamantane class of anti-influenza drugs.
http://en.wikipedia.org/wiki/Protonhttp://en.wikipedia.org/wiki/Ion_channelhttp://en.wikipedia.org/wiki/Proteinhttp://en.wikipedia.org/wiki/Viral_envelopehttp://en.wikipedia.org/wiki/Viral_envelopehttp://en.wikipedia.org/wiki/Influenzahttp://en.wikipedia.org/wiki/Virushttp://en.wikipedia.org/wiki/Disulfide_bondhttp://en.wikipedia.org/wiki/PHhttp://en.wikipedia.org/wiki/Protein_domainhttp://en.wikipedia.org/wiki/Amino_acidhttp://en.wikipedia.org/wiki/N-terminal_endhttp://en.wikipedia.org/wiki/Hydrophobichttp://en.wikipedia.org/wiki/C-terminal_endhttp://en.wikipedia.org/wiki/C-terminal_endhttp://en.wikipedia.org/wiki/Protonhttp://en.wikipedia.org/wiki/Ion_channelhttp://en.wikipedia.org/wiki/Proteinhttp://en.wikipedia.org/wiki/Viral_envelopehttp://en.wikipedia.org/wiki/Viral_envelopehttp://en.wikipedia.org/wiki/Influenzahttp://en.wikipedia.org/wiki/Virushttp://en.wikipedia.org/wiki/Disulfide_bondhttp://en.wikipedia.org/wiki/PHhttp://en.wikipedia.org/wiki/Protein_domainhttp://en.wikipedia.org/wiki/Amino_acidhttp://en.wikipedia.org/wiki/N-terminal_endhttp://en.wikipedia.org/wiki/Hydrophobichttp://en.wikipedia.org/wiki/C-terminal_endhttp://en.wikipedia.org/wiki/C-terminal_end8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
19/77
Function
The M2 protein has an important role in the life cycle of the influenza A
virus. It is located in the viral envelope. It enables hydrogen ions to
enter the viral particle (virion) from the endosome, thus lowering pH
of the inside of the virus, which causes dissociation of the viral matrix
protein M1 from the ribonucleoprotein RNP. This is a crucial step in
uncoating of the virus and exposing its content to the cytoplasm of the
host cell.
Inhibition and resistance
The function of the M2 channel can be inhibited by antiviral drugs
amantadine and rimantadine, which then blocks the virus from taking over
the host cell. The molecule of the drug binds to the transmembrane region,
sterically blocking the channel. This stops the protons from entering the
virion, which then does not disintegrate.
These drugs are sometimes effective against influenza A if given early in
the infection but are always ineffective against influenza B because B
viruses do not possess M2 molecules
However, the M2 gene is susceptible to mutations. When one of five aminoacids in the transmembrane region gets suitably substituted, the virus gains
resistance to the existing M2 inhibitors. As the mutations are relatively
frequent, presence of the selection factors (eg. using amantadine for
http://en.wikipedia.org/wiki/Virionhttp://en.wikipedia.org/wiki/Endosomehttp://en.wikipedia.org/wiki/Ribonucleoproteinhttp://en.wikipedia.org/wiki/Cytoplasmhttp://en.wikipedia.org/wiki/Antiviral_drughttp://en.wikipedia.org/wiki/Antiviral_drughttp://en.wikipedia.org/wiki/Amantadinehttp://en.wikipedia.org/wiki/Rimantadinehttp://en.wikipedia.org/wiki/Genehttp://en.wikipedia.org/wiki/Mutationhttp://en.wikipedia.org/wiki/Amino_acidshttp://en.wikipedia.org/wiki/Amino_acidshttp://en.wikipedia.org/wiki/Virionhttp://en.wikipedia.org/wiki/Endosomehttp://en.wikipedia.org/wiki/Ribonucleoproteinhttp://en.wikipedia.org/wiki/Cytoplasmhttp://en.wikipedia.org/wiki/Antiviral_drughttp://en.wikipedia.org/wiki/Amantadinehttp://en.wikipedia.org/wiki/Rimantadinehttp://en.wikipedia.org/wiki/Genehttp://en.wikipedia.org/wiki/Mutationhttp://en.wikipedia.org/wiki/Amino_acidshttp://en.wikipedia.org/wiki/Amino_acids8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
20/77
treatment of sick poultry) can lead to emergence of a resistant strain ontent
to the cytoplasm of the host cell.
http://en.wikipedia.org/wiki/M2_protein
TREATMENT OF SWINE FLU (PIGS AND HUMAN):
In swine
As swine influenza is rarely fatal to pigs, little treatment beyond rest and
supportive care is required. Instead veterinary efforts are focused on
preventing the spread of the virus throughout the farm, or to other
farms.Vaccination and animal management techniques are most important in
these efforts. Antibiotics are also used to treat this disease, which although
they have no effect against the influenza virus, do help prevent bacterial
pneumonia and othersecondary infections in influenza-weakened herds.
In humans
If a person becomes sick with swine flu, antiviral drugs can make the illness
milder and make the patient feel better faster. They may also prevent serious
flu complications. For treatment, antiviral drugs work best if started soon
after getting sick (within 2 days of symptoms). Beside antivirals, supportive
care at home or in hospital, focuses on controlling fevers, relieving pain and
maintaining fluid balance, as well as identifying and treating any secondary
infections or other medical problems. The U.S. Centers for Disease Controland Prevention recommends the use of Tamiflu (oseltamivir) or Relenza
(zanamivir) for the treatment and/or prevention of infection with swine
influenza viruses; however, the majority of people infected with the virus
make a full recovery without requiring medical attention or antiviral drugs.
http://en.wikipedia.org/wiki/Cytoplasmhttp://en.wikipedia.org/wiki/Pneumoniahttp://en.wikipedia.org/wiki/Secondary_infectionhttp://en.wikipedia.org/wiki/Centers_for_Disease_Control_and_Preventionhttp://en.wikipedia.org/wiki/Centers_for_Disease_Control_and_Preventionhttp://en.wikipedia.org/wiki/Oseltamivirhttp://en.wikipedia.org/wiki/Zanamivirhttp://en.wikipedia.org/wiki/Cytoplasmhttp://en.wikipedia.org/wiki/Pneumoniahttp://en.wikipedia.org/wiki/Secondary_infectionhttp://en.wikipedia.org/wiki/Centers_for_Disease_Control_and_Preventionhttp://en.wikipedia.org/wiki/Centers_for_Disease_Control_and_Preventionhttp://en.wikipedia.org/wiki/Oseltamivirhttp://en.wikipedia.org/wiki/Zanamivir8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
21/77
The virus isolates in the 2009 outbreak have been found resistant to
amantadine and rimantadine.
http://en.wikipedia.org/wiki/Swine_influenza#Treatment
INHABITOR:
Antiviral drugs Amantadine and Rimantadine are the principle inhibitor of
M2 protein of H1N1.
These antiviral medicines prevent the spread of type influenza A by
interfering with the production of the virus inside the body. They do not treat
or protect you against influenza B. These antiviral drugs inhibits the M2
protein by blocking its ion chanel.
These antiviral medicines reduce the severity of influenza (flu) symptoms
and shorten the course of the illness of influenza A. They need to be started
within 48 hours of the first symptoms and continued, usually, for 7 days.
For the past few years, the U.S. Centers for Disease Control and Prevention
(CDC) have advised doctors not to use amantadine (Symadine or
Symmetrel) or rimantadine (Flumadine) to treat or prevent the flu. These
medicines have not worked against most types of the flu virus.
When used to protect people during a flu outbreak, antiviral medicines
usually are used for 7 days but may be continued for 5 to 7 weeks.
http://en.wikipedia.org/wiki/Amantadinehttp://en.wikipedia.org/wiki/Rimantadinehttp://health.yahoo.com/flu-medications/influenza/healthwise--sti150769.htmlhttp://en.wikipedia.org/wiki/Amantadinehttp://en.wikipedia.org/wiki/Rimantadinehttp://health.yahoo.com/flu-medications/influenza/healthwise--sti150769.html8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
22/77
In healthy young adults and children, antiviral medicines can be very
effective in preventing influenza A during an outbreak. But these antiviral
medicines do not always treat or prevent the flu.
When given within 48 hours after symptoms begin, they may reduce
symptoms, shorten the length of influenza A illness by 1 or 2 days, and
allow for a faster return to usual activities.
Side Effects:
Side effects have been reported with both amantadine and rimantadine:
Amantadine can cause sleeplessness (insomnia), hallucinations, and
agitation in a small number of people (2%).
Rimantadine often causes side effects that affect the digestive system,
such as an upset stomach, nausea, and loss of appetite.
More serious but less frequent side effects (seizures, confusion) have been
reported in older adults and, most commonly, in adults who have seizure
disorders. Lowering the dose reduces these side effects without reducing the
effectiveness of the medication.
Side effects decrease after about 1 week of use and reverse as soon as
treatment stops.
http://health.yahoo.com/flu-medications/insomnia/healthwise--zq1015.htmlhttp://health.yahoo.com/flu-medications/hallucinations/healthwise--sth149536.htmlhttp://health.yahoo.com/flu-medications/insomnia/healthwise--zq1015.htmlhttp://health.yahoo.com/flu-medications/hallucinations/healthwise--sth149536.html8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
23/77
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
24/77
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
25/77
Mark S.P. Sansom and Ian D. Kerr . : a molecular modelling study of
the ion channel ,Received September 3, 1992;revised October 22, 1992;
accepted October 28, 1991.
The influenza A M2 proteinforms cation-selective ion channelswhich
are blocked by the anti-influenza drug amantadine. A molecularmodel
of the M2 channel is presented in which a bundle of fourparallel M2
transbilayer helices surrounds a central ion-permeable pore. Analysis
of helix amphipathicity was used to aid determination of the
orientation of the helices about their long axes. Thehelices are tilted
such that the N-terminal mouth of the pore is wider than the C-
terminal mouth. The channel is lined by residues V27, S31 and I42.
Residues D24 and D44 are located at opposite mouths of the pore,
which is narrowest in the vicinity of I42. Energy profiles for
interaction of the channel with Na+, amantadine-H+ and
cyclopentylamine-H+ are evaluated. The interaction profile for Na+
exhibits three minima, one at each
mouth of the pore, and one in theregion of residue S31. Theamantadine-H+ profile exhibits a minimum
close to S31 and abarrier near residue I42. This provides a molecular
model for amantadine-H+ block of M2 channels. The profile for
cyclopentylamine-H+ does not exhibit such a barrier. It is predicted
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
26/77
that cyclopentyl-amine-H+ will not act as an M2 channel blocker
(Mark S.P. Sansom et.al 1992).
Takeda M, Pekosz A, Shuck K, Pinto LH, Lamb RA. Influenza a virus
M2 ion channel activity is essential for efficient replication in tissue
culture. J Virol. 2002 Feb;76(3):1391-9.
The amantadine-sensitive ion channel activity of influenza A virus M2
protein was discovered through understanding the two steps in the
virus life cycle that are inhibited by the antiviral drug amantadine:
virus uncoating in endosomes and M2 protein-mediated equilibration
of the intralumenal pH of the trans Golgi network. Recently it was
reported that influenza virus can undergo multiple cycles of
replication without M2 ion channel activity (T. Watanabe, S.
Watanabe, H. Ito, H. Kida, and Y. Kawaoka, J. Virol. 75:5656-5662,
2001). An M2 protein containing a deletion in the transmembrane(TM) domain (M2-del(29-31)) has no detectable ion channel activity,
yet a mutant virus was obtained containing this deletion. Watanabe
and colleagues reported that the M2-del(29-31) virus replicated as
efficiently as wild-type (wt) virus. We have investigated the effect of
amantadine on the growth of four influenza viruses: A/WSN/33;
N31S-M2WSN, a mutant in which an asparagine residue at position
31 in the M2 TM domain was replaced with a serine residue;
MUd/WSN, which possesses seven RNA segments from WSN plus
the RNA segment 7 derived from A/Udorn/72; and A/Udorn/72.
N31S-M2WSN was amantadine sensitive, whereas A/WSN/33 was
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Takeda%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlushttp://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pekosz%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlushttp://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Shuck%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlushttp://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pinto%20LH%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlushttp://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lamb%20RA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlushttp://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Takeda%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlushttp://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pekosz%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlushttp://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Shuck%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlushttp://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pinto%20LH%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlushttp://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Lamb%20RA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
27/77
amantadine resistant, indicating that the M2 residue N31 is the sole
determinant of resistance of A/WSN/33 to amantadine. The growth of
influenza viruses inhibited by amantadine was compared to the growth
of an M2-del (29-31) virus. We found that the M2-del (29-31) virus
was debilitated in growth to an extent similar to that of influenza virus
grown in the presence of amantadine. Furthermore, in a test of
biological fitness, it was found that wt virus almost completely
outgrew M2-del(29-31) virus in 4 days after co-cultivation of a 100:1
ratio of M2-del (29-31) virus to wt virus, respectively. We conclude
that the M2 ion channel protein, which is conserved in all known
strains of influenza virus, evolved its function because it contributes to
the efficient replication of the virus in a single cycle (Takeda M et.al
2002)
Thanyada Rungrotmongkol, Pathumwadee Intharathep a, Maturos
Malaisree a, Nadtanet Nunthaboot c, Nopphorn Kaiyawet a, Pornthep
Sompornpisut a, Sanchai Payungporn d, Yong Poovorawan d, Supot
Hannongbua a,Susceptibility of antiviral drugs against 2009 influenza A
(H1N1) virus Biochemical and Biophysical Research Communications
Due to antigenic differences amongst influenza A strains, the current
seasonal influenza vaccines cannot provide protection against this new
strain of A (H1N1) influenza virus. Up to date, there are two classes of
anti-influenza agents:
NA inhibitors, oseltamivir and zanamivir, protecting the release and spread
of progeny virions
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Takeda%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlushttp://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Takeda%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
28/77
(ii) adamantane derivatives, amantadine and rimantadine, preventing the
proton transfer in the M2 ion-channel. The A (H1N1) viruses isolated
from patients in USA and Mexicoare sensitive to NA inhibitors but
show resistance to adamantane derivatives. To gain the fundamental
knowledge on the structure and the drugtarget interactions of the new
strain of influenza A (H1N1) virus, homology modeling and molecular
dynamics (MD) simulations were carried out on the three inhibitor
enzyme complexes: OTV-NA, AMT-M2 and RMT-M2. The present
study is an extension from, and is compared to, our previous works on
avian influenzaH5N1 virus were focused to understand the structural
properties, intermolecular interactions and predictive inhibitory
potencies of both wild- and mutant-type viruses at the NA and HA
(Thanyada Rungrotmongkol et.al 2009).
Kanta Subbarao & Tomy Joseph. Scientific barriers to developing
vaccines against avian influenza viruses. Nature Reviews Immunology 7,
267-278 (April 2007)
The influenza A virus particle has a lipid envelope that is derived from the
host cell membrane. Three envelope proteins haemagglutinin (HA),
neuraminidase (NA) and an ion channel protein (matrix protein 2, M2)
are embedded in the lipid bilayer of the viral envelope. HA (rodshaped) and NA (mushroom shaped) are the main surface glycoproteins
of influenza A viruses. The ratio of HA to NA molecules in the viral
envelope usually ranges from 4:1 to 5:1. b | The HA glycoprotein is
synthesized as an HA0 molecule that is post-translationally cleaved into
http://www.nature.com/nri/journal/v7/n4/full/nri2054.htmlhttp://www.nature.com/nri/journal/v7/n4/full/nri2054.htmlhttp://www.nature.com/nri/journal/v7/n4/full/nri2054.htmlhttp://www.nature.com/nri/journal/v7/n4/full/nri2054.html8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
29/77
HA1 and HA2 subunits; this cleavage is essential for virus infectivity.
The HA glycoprotein is responsible for binding of the virus to sialic-
acid residues on the host cell surface and for fusion of the viral
envelope with the endosomal membrane during virus uncoating. The
NA glycoprotein cleaves sialic-acid receptors from the cell membrane
and thereby releases new virions from the cell surface. M2 functions as
a pH-activated ion channel that enables acidification of the interior of
the virion, leading to uncoating of the virion. Matrix protein 1 (M1),
which is the most abundant protein in the virion, underlies the viral
envelope and associates with the ribonucleoprotein (RNP) complex.
Inside the M1 inner layer are eight single-stranded RNA molecules of
negative sense that are encapsidated with nucleoprotein (NP) and
associated with three RNA polymerase proteins , polymerase basic
protein 1 (PB1), PB2 and polymerase acidic protein (PA) , to form the
RNP complex. The PB1, PB2 and PA proteins are responsible for the
transcription and replication of viral RNA. The virus also encodes a
non-structural protein (NS) that is expressed in infected cells and a
nuclear export protein (NEP). The location of NEP in the virion is not
known (Kanta Subbarao et. al. 2007).
.
.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
30/77
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
31/77
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
32/77
Tools and techniques:
I used a variety of tools and a large number of techniques in completion of
this project. These all tools and techniques were unknown to me before and I
have used these for the first time.
HARDWARE CONFIGURATION:
Processor - Intel Pentium P4 2.8GHz D2
RAM - 1 GB
Hard disk 160 GB
Server computer platform:
LINUX:
We did our search for the best operating system for our life science and we
use LINUX operating system. Nowadays,Linux is one of the most flexible
and popular operating systems for biological purposes. Linux is used
because of the following reasons:
Cost: For desktop or home use, Linux is very cheap or free,
Windows is expensive: For server use, Linux is very cheap compared
to Windows.
Running from CD: Linux can run from a CD. But for Windows, it
has to first be installed to hard disk.
Viruses: Compared to Windows, Linux is virus-free.
Security: You have to log on to Linux with a user id and password.
This is not true of Windows.
Bugs: Linux has a reputation for fewer bugs than Windows,
Hardware the OS runs on: Linux runs on many different hardware
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
33/77
platforms, not so with Windows.
Multiple Users: Linux is a multi- user system; Windows is
not.
Traditional comparative genomics process is a time consuming as well as
money. The introduction ofHigh Performance Computing and Networking
(HPCN) techniques in this process would decrease the costs and the time
necessary to compare the genomes. The current project focuses on the
Computer Assisted motifs finding using High Performance Computing &
Networking(HPCN) as a tool to improve the process of comparing genomes.
Computational power is now available in the form ofLinux Cluster
Technologies.
Client computer platform:
WINDOWS Operating System
OPERATING SYSTEM: PCQ LINUX version 2004, WINDOWS -XP andLIVE CDs.
TOOLS AND SOFTWARES:
ON LINE SOFTWARES: PDB, KEGG, NCBI, and
UNIPROT.
OFFLINE SOFTWARES: PYMOL, GHEMICAL, OPEN
BABEL, FRED, VIDA.
SOFTWARES:
Supercomputing in Linux:
A step-by-step guide on how to set up a cluster of PCQ Linux machines for
supercomputing .To keep it simple, we start with a cluster of three machines.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
34/77
One will be the server and the other two will be the nodes. However,
plugging in additional nodes is easy and will tell the modification to
accommodate additional nodes. Instead of two nodes, we can have a single
node. So, even if we have two PCs, we can build a cluster.
Set up server hardware:
We should have at least a 2 GB or bigger hard disk on the server. It should
have a graphics card that is supported by PCQ Linux 7.1 and a floppy drive.
We also need to plug in two network cards, preferably the faster PCI cards
instead of ISA, supported by PCQ Linux. Why two network cards? Adhering
to the standards for cluster setups, if the server node needs to be connected to
the outside (external) network, Internet or your private network the nodes in
the cluster must be on a separate network. This is needed if we want to
remotely execute programs on the server. If not, we can do away with a
second network card for the external network. . Hence, on the server, one
network card (called external interface) will be connected to the Labs
network and the other network card (internal interface) will be connected to
a switch. We used a 100/10 Mbps switch. A 100 Mbps switch is
recommended because the faster the speed of the network, the faster is the
message passing. All cluster nodes will also be connected to the switch.
PYMOL:
PYMOL is a molecular graphics system with an embedded Python
interpreter designed for real-time visualization and rapid generation of high-
quality molecular graphics images and animations. It can also perform many
other valuable tasks (such as editing PDB files) to assist you in your
research. The extensible core PyMOL module (hosted here at Source Forge)
is available free to everyone via the "Python" license (a simple BSD-like
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
35/77
permission statement), but we ask all users to purchase a license and
maintenance agreement in order to cover our development and support costs.
In order to motivate such sponsorship, we offer support and other incentives
to PyMOLs licensees with current maintenance subscriptions. In this way,
we seek to insure the viability of the Open-Source project by providing a
specific incentive (or reward) for outside support. However, our hope is that
only a small subset of PyMOL's total value will need to be restricted to
Incentive packages just enough to justify regular contributions and keep the
project self-sustaining.
Fig: PYMOL software home page.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
36/77
FRED RECEPTOR
Fred receptor is a wizard like graphical utility that prepares an active site for
docking with FRED, Open- Eyes docking program. fred receptor was
created to make preparing an active site a more intuitive process by allowing
the user to visualize the active site and how it is setup, however FRED does
not require that the active site be prepared with fred receptor. Input to fred
receptor is the structure of the target protein, generally from an X-ray
crystallography experiment. Output is a receptor file, which is a specialized
OEB (Open Eyes molecule format) file, used by FRED.
Fig: FRED RECEPTOR home page.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
37/77
F.R.E.D
F.R.E.D. (Fast Rigid Exhaustive Docking) is a protein-ligand docking
program, which takes a multiconformer library/database and receptor file as
input and outputs molecules of the input database most likely to bind to the
receptor. FRED is a command line program, although a GUI is available to
setup and create receptor files prior to docking. Typical docking time for
FRED is a few seconds per ligand. FRED jobs can also be easily distributed
over multiple computers/processors using PVM to further reduce docking
time.
The following structure-based scoring functions are available in FRED.
These scoring functions also have MASC variant.
1. SHAPEGAUSS: A shape-based scoring function that uses smooth
Gaussian functions to represent the shapes of molecules.
2. PLP: or Piecewise Linear Potential
3. CHEMGAUSS2: Version 2 of the Chemgauss scoring function, which
uses smooth Gaussian functions to represent the shape and chemistry of
molecules.
4. CHEMGAUSS3: Version 3 of the Chemgauss scoring function, which
uses smooth Gaussian functions to represent the shape and chemistry of
molecules.
Fred receptor is a wizard like graphical utility that prepares an active site for
docking with FRED, Open-Eyes docking program. fred receptor was
created to make preparing an active site a more intuitive process by allowing
the user to visualize the active site and how it is setup, however FRED does
not require that the active site be prepared with fred receptor. Input to Fred
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
38/77
receptor is the structure of the target protein, generally from an X-ray
crystallography experiment. Output is a receptor file, which is a specialized
OEB (Open Eyes molecule format) file, used by FRED.
PROTOTYPE SOFTWARE:
The Fred receptor program is prototype software, which means the overall
design of this program may be changed in future versions. This is the first
time a GUI has been created to assist Fred, or any OpenEye computational
program, and as such is somewhat experimental. We expect and hope to get
feedback from users regarding the Fred receptor program. Based on that
feedback and other considerations future versions of Fred receptor may have
a substantially different look and feel as well as somewhat modified
functionality. For example the next version of Fred may have a completely
graphical interface that the Fred receptor programs functionality is merged
into.
Prototype software does not mean beta software. The Fred receptor is a
complete stable utility to assist Fred users in preparing their active site for
docking.
OPEN BABEL:
Open babel is free software, a chemical expert system mainly used for
converting chemical file formats. Due to the strong relationship to
informatics this program belongs more to the category cheminformatics than
to molecular modeling. It is available for Windows, UNIX, and Mac OS. It
is distributed under the GNU GPL. The project's stated goal is: "Open Babel
is a community-driven scientific project assisting both users and developers
as a cross-platform program and library designed to support molecular
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
39/77
modeling, chemistry, and many related areas, including interconversion of
file formats and data. Open Babel is a full chemical software toolbox. In
addition to converting file formats, it offers a complete programming library
for developing chemistry software. The library is written primarily in C++
and also offers interfaces to other languages (e.g., Perl, Python, Ruby, and
Java) using essentially the same API. This documentation outlines the Open
Babel programming interface, providing information on all public classes,
methods, and data. In particular, strives to provide as much (or as little)
detail as needed. More information can also be found on the main website
and through the Open babel-discuss mailing list. Open babel is a
community-driven scientific project including both cross-platform programs
and a developer library designed to support molecular modeling, chemistry,
and many related areas, including interconversion of file formats and data.
OPEN BABEL GUI:
A graphical user interface to babel's functionality. You can start Open Babel
GUI using the shortcut in the Start Menu. You can copy this onto your
desktop to make it easier to access it. This graphical interface is an
alternative to a command line and has the same capabilities. It is written
using wxWidgets and has the capability to be compiled on most platforms.
Currently it is available only on Windows and is available in the compiled
download. At present the interface is entirely text with no graphical display
of molecular structure. It does however provide an environment likely to be
familiar to Windows users and displays the options available rather than the
user having to remember them.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
40/77
Fig: This figure shows home page of open babel GUI.
OMEGA:
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
41/77
Omega builds initial models of structures by assembling fragment templates
along sigma bonds. Input molecules graphs are fragmented at exocyclic
sigma and carbon to heteroatom acyclic (but not exocyclic) sigma bonds.
Fig: OMEGA software
VIDA:
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
42/77
VIDA is Open Eyes main visualization application designed to intuitively
and effortlessly handle very large data sets while still generating extremely
high quality images. VIDA provides multiple modes of display including
1D, 2D, and 3D displays. Furthermore, VIDA is an excellent interface for
data analysis as it contains a chemically-aware spreadsheet and a powerful
list-based architecture.
Fig: VIDA home page.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
43/77
List of online and off line tools:
S.No.
Tools / Servers /
Databases
Used
Used for
1. NCBI Sequence Database
2. PDB Protein structure
3. PYMOL Protein structure visualization
4. FRED RECEPTOR Active site finding
5. PUBCHEM Ligand libraroy
6. OPEN BABEL Converting chemical files
7. OMEGA Fragment of Chemical Compounds9. FRED Docking
10 VIDA Docking visualization
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
44/77
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
45/77
Protein searching:
In first step I retrieved target protein (M2 Protein) sequence by
usingNCBI,provides scientific community.
Fig: This image showing some information on NCBI.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
46/77
Fig:This image showing information about M2 Protein on NCBI .
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
47/77
Fig : Protein sequence of M2 protein by using FASTA format.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
48/77
Protein structure:
After taking the M2 protein sequence, I download the struture fromPDB.
Fig: This image showing some information of various M2 protein on
PDB.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
49/77
Fig: This image showing some information on PDB.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
50/77
Protein Study by Pymol:
After downloading the M2 protein sequence we use the
Pymol visualization software to study the 3-D structure of
M2protein.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
51/77
Fig: Image showing 3-D structure of M2 protein on Pymol.
Protein study: For further study (Helix, loops, chains etc)of M2 protein we use the Pymol visualization software.
1. Load the PDB file
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
52/77
File -> Open -> 1w2i.pdb2. Hide everything and then show protein carttonPyMOL> hide everything, allPyMOL> show cartoon, all
Fig :Visualization of target M2 protein structure on pymol.In this
image pymol shows four chains.
3. Color the helix, sheet, and loopPyMOL> color purple, ss hPyMOL> color yellow, ss sPyMOL> color green, ss ""
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
53/77
Fig: Image showing the helix in purpel color of M2 protein on Pymol.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
54/77
Fig : This image showing helix of M2 protein on Pymol.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
55/77
4. Color chain A and BPyMOL> color red, chain APyMOL> color blue, chain B
Fig : Image showing the four chains of M2 protein by four different
colour on Pymol.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
56/77
Fig: This image showing the surface structure of M2 protein on
PYMOL. The four colours showing the four chains of M2 protein.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
57/77
Active site finding :
In next step to find active site of target protein we used the softwareFRED RECEPTOR.
Fig : This image showing active site of M2 protein whitch is kept in box.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
58/77
Ligand libraroy :
The next step is to creat ligand liberary based on model inhabitor
amantadine and rimantadine.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
59/77
Fig : This image showingsomeinformation for modal ligand onPUBCHEM.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
60/77
Fig : This image showingsomeinformation about amantadine ligand onPUBAHEM .
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
61/77
Fig : This image showingsomeinformation about rimantadine ligand on
PUBCHEM.
After that I collected the 100 inhibitors library for next docking step.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
62/77
Fig : This image showingthe ligand library.
Running process of docking:
1) Prepare the receptor and find active sites via FRED receptor and save
file in .oeb format.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
63/77
2) Library preparation: collect SDF file from PUBCHEM, NCBI.
a) Open the OPEN BABEL software and convert all SDF files
into MOL2 format.
3) Merge all the converted SDF files into a single file by the below given
command in linux operating system.
4) For the preparation of fragments of all chemical compounds as a
merged file by OMEGA.
C) Save the target protein file and omega fragment file in the
directory of FRED.
5) For the final step of docking proceed with the FRED software
a) Run the FRED software in LINUX and give the following
command:
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
64/77
Fig: fragment and conformation of files through OMEGA
software
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
65/77
Fig: Showing monitors performance during docking.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
66/77
Fig: This image is showing the files formed during docking process.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
67/77
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
68/77
RESULTS & DISCUSSION
CADD is a technique to perform the initial results of any pharmaceutical
products. This is fully based on computer and computing power and I have
used this in my project and entitled as A STUDY ON COMPUTER AIDED
DRUG DESIGN FOR M2 PROTEIN OF H1N1 which deals with a real life
problem for human health.
M2 protein (matrix protein) is involved in causing swine flu disease. It
enables hydrogen ions to enter the viral particl from the endosome, thus
lowering pH inside the viral partical, which causes dissociation of the viral
partical. This is a crucial step in uncoating of the virus and exposing its
content to the cytoplasm of the host cell.
I have used M2 protein as target and collected the possible 100 ligands
library from the PUBCHEM and through virtual screening I found out the
minimum energy inhibitor CID_44918, IUPAC name-: 1-(1-aminopentyl)
adamantane hydrochloride.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
69/77
Fig: This image is showing shapegauss file having the shapegauss scores ofall the ligands used in the docking.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
70/77
Fig: This image is showing some information of finally selected ligand onPUBCHEM.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
71/77
Fig: This image is showing some information of finally selected adamantanehydrochlorideadamantane hydrochloride ligand on PUBCHEM.
Docking visualization:
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
72/77
After the docking process we study the result by using docking visualizationsoftware, VIDA.
Fig: This image is showing the binding of selected ligand with target proteinon VIDA.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
73/77
Fig: This image is showing the binding of selected ligand with target proteinwith different angle.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
74/77
Fig: This image is showing the binding of selected ligand with target protein,kept in net.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
75/77
Fig: This image is showing the binding of selected ligand with target proteinhelix.
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
76/77
8/2/2019 A STUDY ON COMPUTER AIDED DRUG DESIGN FOR M2 PROTEIN IN H1N1
77/77
References